Yamm Megamenu
×

CLONIDINE SUPPRESSION TEST FOR PLASMA CATECHOLAMINES LabTest

KayaWell Icon

CLONIDINE SUPPRESSION TEST FOR PLASMA CATECHOLAMINES LabTest
455 Views
By KayaWell Expert

Map Data
Map data ©2020
Map DataMap data ©2020
Map data ©2020

Sponsored

Knowledge Base

CLONIDINE SUPPRESSION TEST FOR PLASMA CATECHOLAMINES LabTest

The diagnosis of pheochromocytoma/paraganglioma (PPGL) involves detection of elevated levels of plasma and/or 24-h urine catecholamines and/or their metabolites, including metanephrines. Although these tests are reasonably sensitive, false-positive results are often encountered. Follow-up tests can provide additional information to correctly diagnose PPGL. In this regard, the utility of the urinary clonidine suppression test (UCST) remains unknown.

Clonidine significantly decreased urine creatinine-corrected norepinephrine and normetanephrine in patients without PPGL (P < 0.001 pairwise) but not in patients with PPGL. Epinephrine and metanephrine levels were not significantly reduced in either group. Receiver operating characteristic (ROC) area under the curve was 0.955 [95% confidence interval (95% CI) 0.906-1.000, P < 0.001] and 0.823 (95% CI 0.706-0.940, P < 0.001) for norepinephrine and normetanephrine, respectively. Optimal cut-offs were established at 50 and 15% reductions in norepinephrine and normetanephrine, respectively, which provided high sensitivities (93.3% for both) and negative predictive values (97.4 and 96.3%). When both were concordant, higher diagnostic accuracy was achieved (100% sensitivity, 92.0% specificity). Results were similar in subgroups of individuals with borderline initia

https://www.ncbi.nlm.nih.gov
https://www.ncbi.nlm.nih.gov
CLONIDINE SUPPRESSION TEST FOR PLASMA CATECHOLAMINES LabTest

Comments